See more : Hawthorn Bancshares, Inc. (HWBK) Income Statement Analysis – Financial Results
Complete financial analysis of PolyPid Ltd. (PYPD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PolyPid Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Hangzhou Century Co., Ltd. (300078.SZ) Income Statement Analysis – Financial Results
- Mazda Limited (MAZDA.NS) Income Statement Analysis – Financial Results
- Snap Inc. (SNAP) Income Statement Analysis – Financial Results
- Fullerton Technology Co., Ltd. (6136.TW) Income Statement Analysis – Financial Results
- China Communications Services Corporation Limited (0552.HK) Income Statement Analysis – Financial Results
PolyPid Ltd. (PYPD)
About PolyPid Ltd.
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.82M | 1.72M | 1.12M | 1.01M | 947.00K | 411.00K | 205.00K | 127.00K | 108.00K | 0.00 | 0.00 |
| Gross Profit | -1.82M | -1.72M | -1.12M | -1.01M | -947.00K | -411.00K | -205.00K | -127.00K | -108.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 16.15M | 27.99M | 30.42M | 16.95M | 14.08M | 12.55M | 9.74M | 7.71M | 5.63M | 2.64M | 1.38M |
| General & Administrative | 0.00 | 8.01M | 9.48M | 7.70M | 4.48M | 5.27M | 4.06M | 2.55M | 2.93M | 938.00K | 410.00K |
| Selling & Marketing | 0.00 | 2.89M | 2.97M | 1.61M | 887.00K | 549.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.90M | 10.90M | 12.45M | 9.32M | 4.48M | 5.81M | 4.06M | 2.55M | 2.93M | 938.00K | 410.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 21.05M | 38.89M | 42.88M | 26.27M | 18.56M | 18.36M | 13.80M | 10.26M | 8.57M | 3.58M | 1.79M |
| Cost & Expenses | 22.87M | 38.89M | 42.88M | 26.27M | 18.56M | 18.36M | 13.80M | 10.26M | 8.57M | 3.58M | 1.79M |
| Interest Income | 548.00K | 267.00K | 468.00K | 474.00K | 60.00K | 126.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.71M | 1.02M | 0.00 | 17.00K | 15.00K | 42.00K | 40.69M | 1.13M | -1.53M | 0.00 | 0.00 |
| Depreciation & Amortization | 1.82M | 1.72M | 1.12M | 1.01M | 947.00K | 411.00K | 205.00K | 127.00K | 108.00K | 71.00K | 60.00K |
| EBITDA | -20.26M | -36.37M | -41.48M | -35.86M | -5.94M | -42.15M | -13.60M | -10.13M | -7.95M | -3.51M | -1.73M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -22.87M | -38.89M | -42.88M | -26.27M | -18.56M | -18.36M | -13.80M | -10.26M | -11.28M | -3.58M | -1.79M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -929.00K | -540.00K | 544.00K | -10.60M | 11.66M | 24.28M | -40.69M | -1.13M | -1.18M | -305.00K | -3.00K |
| Income Before Tax | -23.80M | -39.43M | -42.33M | -36.87M | -6.91M | 5.92M | -54.49M | -11.39M | -9.75M | -3.88M | -1.79M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 69.00K | 97.00K | -1.62M | -1.55M | -11.66M | -24.28M | 40.69M | 1.13M | -1.53M | 305.00K | 3.00K |
| Net Income | -23.87M | -39.53M | -40.71M | -35.32M | 4.75M | 5.92M | -54.49M | -11.39M | -8.22M | -3.88M | -1.79M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -16.99 | -61.04 | -65.24 | -110.59 | 10.72 | 13.35 | -185.29 | -38.74 | -18.81 | -19.79 | -4.04 |
| EPS Diluted | -16.99 | -61.04 | -65.24 | -110.59 | 10.72 | 13.35 | -185.29 | -38.74 | -18.81 | -19.79 | -4.04 |
| Weighted Avg Shares Out | 1.40M | 647.56K | 624.05K | 319.41K | 443.22K | 443.22K | 294.07K | 294.07K | 437.07K | 196.22K | 443.22K |
| Weighted Avg Shares Out (Dil) | 1.40M | 647.56K | 624.05K | 319.41K | 443.22K | 443.22K | 294.07K | 294.07K | 437.07K | 196.22K | 443.22K |
PolyPid Announces Positive Preclinical Data from OncoPLEX Intra-Tumoral Cancer Therapy Program
Single Local Treatment of OncoPLEX Showed Improved Overall Survival and Significantly Less Tumor Recurrence, and Reduced Systemic Toxicity Compared to Multiple Injections with Standard Systemic Chemotherapy in a Syngeneic Mouse Model for Solid Tumors of Colon Carcinoma
PolyPid Initiates SHIELD II: Second Phase 3 Clinical Trial of D-PLEX₁₀₀ for the Prevention of Post-Abdominal Surgery Incisional Infections
Enrollment in SHIELD I, the First Phase 3 Clinical Trial Continues to Progress, with Top-line Data Anticipated in Second Half of 2021
PolyPid to Host Key Opinion Leader Call Discussing D-PLEX₁₀₀ and the Prevention of Surgical Site Infections
PETAH TIKVA, Israel, Dec. 03, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will host a key opinion leader...
PolyPid Ltd. (PYPD) CEO Amir Weisberg on Q3 2020 Results - Earnings Call Transcript
PolyPid Ltd. (PYPD) CEO Amir Weisberg on Q3 2020 Results - Earnings Call Transcript
PolyPid Ltd. Provides Corporate Update and Reports Third Quarter 2020 Financial Results
• Over 50% of p lanned 60 centers for ongoing Phase 3 SHIELD I t rial of D-PLEX 100 in a bdominal s urgery have r eceived IRB approval
PolyPid to Participate in Three Upcoming Investor Conferences
PETAH TIKVA, Israel, Nov. 04, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will present at two investor conferences...
PolyPid to Report Third Quarter 2020 Financial Results and Operational Highlights on November 11, 2020
PETAH TIKVA, Israel, Oct. 28, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will report its third quarter 2020...
Source: https://incomestatements.info
Category: Stock Reports